

**Supplementary Table 5.** Prescription pattern after discontinuation of 4th OHA

Prescription pattern	Discontinued agents	No. (%)
Discontinuation of quadruple combination of OHAs		87 (100)
Discontinuation of agent newly added as quadruple combination		47 (54.0)
	Thiazolidinedione	23 (26.4)
	SGLT2 inhibitor	12 (13.8)
	DPP4 inhibitor	6 (6.9)
	Sulfonylurea or glinide	3 (3.4)
	$\alpha$ -Glucosidase inhibitor	3 (3.4)
Discontinuation of other agent		22 (25.3)
	Metformin	7 (8.0)
	DPP4 inhibitor	4 (4.6)
	SGLT2 inhibitor	4 (4.6)
	Thiazolidinedione	3 (3.4)
	Sulfonylurea or glinide	3 (3.4)
	$\alpha$ -Glucosidase inhibitor	1 (1.2)
Initiation of injectables (insulin and/or GLP-1 RA)		18 (20.1)

OHA, oral hypoglycemic agent; SGLT2, sodium-glucose cotransporter 2; DPP4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist.